AstraZeneca: deal with Japan's Daiichi Sankyo
(CercleFinance.com) - AstraZeneca announced on Monday the signature of an agreement with Japan's Daiichi Sankyo for the development and commercialisation of a novel antibody for the treatment of cancer tumours.
The Anglo-Swedish biopharmaceutical group specifies that the partnership will focus on DS-1062, an antibody targeting a membrane glycoprotein present in numerous tumours, including lung and breast cancer, two specialities that are considered "strategic" by AstraZeneca.
Under the terms of the agreement, AstraZeneca will make an initial payment to Daiichi Sankyo of about 1 billion dollars, which could then receive up to 1 billion dollars depending on the project's progress and up to 4 billion dollars in milestone payments.
AstraZeneca also announced on Monday that the European Commission has granted marketing authorisation in Europe for its Imfinzi drug for the treatment of widespread non-small cell lung cancer.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
The Anglo-Swedish biopharmaceutical group specifies that the partnership will focus on DS-1062, an antibody targeting a membrane glycoprotein present in numerous tumours, including lung and breast cancer, two specialities that are considered "strategic" by AstraZeneca.
Under the terms of the agreement, AstraZeneca will make an initial payment to Daiichi Sankyo of about 1 billion dollars, which could then receive up to 1 billion dollars depending on the project's progress and up to 4 billion dollars in milestone payments.
AstraZeneca also announced on Monday that the European Commission has granted marketing authorisation in Europe for its Imfinzi drug for the treatment of widespread non-small cell lung cancer.
Copyright (c) 2020 CercleFinance.com. All rights reserved.